SCHEMBL30089448

SCHEMBL30089448

CC(=O)N[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](NC(C)=O)C(O)O[C@@H]2CO)O[C@H](COS(=O)(=O)O)[C@H](O)[C@@H]1O

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CD69 Q07108 1/20 0.52
▸ LGALS3 P17931 5/20 0.52
▸ LGALS8 O00214 1/20 0.49
▸ LGALS4 P56470 1/20 0.49
▸ CHIA Q9BZP6 1/20 0.49
▸ ALDH1A1 P00352 1/20 0.46
▸ THRB P10828 1/20 0.46
▸ HPSE Q9Y251 4/20 0.46
▸ MAPK1 P28482 2/20 0.45
▸ F10 P00742 1/20 0.44
▸ LGALS1 P09382 1/20 0.44
▸ LGALS7; LGALS7B P47929 1/20 0.44
▸ PTN P21246 1/20 0.44
▸ MDK P21741 1/20 0.44
▸ BDNF P23560 1/20 0.44
▸ F2 P00734 1/20 0.42
▸ SERPINC1 P01008 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20390684 0.97 CD69 (0.53) CD69LGALS3LGALS8LGALS4CHIA
SCHEMBL20390670 0.97 CD69 (0.53) CD69LGALS3LGALS8LGALS4CHIA
SCHEMBL20390696 0.93 CD69 (0.50) CD69LGALS3LGALS8LGALS4CHIA
SCHEMBL20390719 0.93 CD69 (0.50) CD69LGALS3LGALS8LGALS4CHIA
SCHEMBL16802126 0.90 LGALS3 (0.47) CD69LGALS3LGALS8LGALS4CHIA
SCHEMBL16433860 0.90 LGALS3 (0.47) CD69LGALS3LGALS8LGALS4CHIA
SCHEMBL14597949 0.90 LGALS3 (0.47) CD69LGALS3LGALS8LGALS4CHIA
SCHEMBL16623683 0.90 LGALS3 (0.47) CD69LGALS3LGALS8LGALS4CHIA
SCHEMBL18024607 0.90 LGALS3 (0.47) CD69LGALS3LGALS8LGALS4CHIA
SCHEMBL20390690 0.90 LGALS3 (0.47) CD69LGALS3LGALS8LGALS4CHIA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630593-B2 Method of killing leukemia cells by administration of recombinant'Y3 proteins UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2026-05-19 — — US disclosed
US-20230272019-A1 FUNGAL GLYCAN BINDING PROTEIN WHICH POSSESSES ANTIVIRAL AND ANTICANCER ACTIVITY UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2023-08-31 — — US disclosed
US-11512119-B2 Fungal glycan binding protein which possesses antiviral and anticancer activity UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2022-11-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12630593-B2 Method of killing leukemia cells by administration of recombinant'Y3 proteins L3MBTL3, CHI3L1, BCL3 CD69 744/4885LGALS3 32/4885LGALS8 886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback